TU

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

van Oosterhout et al.

**Serial No.:** 09/668,555

Filed: September 22, 2000

**For:** METHODS AND MEANS FOR THE TREATMENT OF IMMUNE RELATED

**DISEASES** 

Confirmation No.: 2631

Examiner: R. B. Schwadron

Group Art Unit: 1644

Attorney Docket No.: 2183-4541US

NOTICE OF EXPRESS MAILING

 Express Mail Mailing Label Number:
 EV092593885US

 Date of Deposit with USPS:
 June 11, 2002

 Person making Deposit:
 Jon Wentz

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

06/18/2002 HDENESS1 00000030 09668555

01 FC:126

180.00 OP

**Serial No.:** 09/668,555

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

## Other Documents

Ypke et al., A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease, Clinical Observations, Interventions, and Therapeutic Trials, June 15, 2000, pp. 3693-701, Vol. 95, No. 12.

Applicants offer to supply any explanation or discussion of the documents that the Examiner feels is necessary or desirable and which is requested.

This Supplemental Information Disclosure Statement is being mailed after the mailing date of the first Office Action. The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,

Assen C. Turner

Registration No. 33,041 Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: June 11, 2002

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents